A Study Assessing The Pharmacokinetics, Pharmacodynamics, Safety And Tolerability Of Subcutaneous Bolus And Subcutaneous Infusion Of Cenderitide In Patients With Chronic Heart Failure With Volume Overload (HF)

Trial Profile

A Study Assessing The Pharmacokinetics, Pharmacodynamics, Safety And Tolerability Of Subcutaneous Bolus And Subcutaneous Infusion Of Cenderitide In Patients With Chronic Heart Failure With Volume Overload (HF)

Completed
Phase of Trial: Phase I

Latest Information Update: 17 Oct 2012

At a glance

  • Drugs Cenderitide (Primary)
  • Indications Chronic heart failure
  • Focus Biomarker; Pharmacokinetics
  • Most Recent Events

    • 29 Mar 2012 Results were presented at the American College of Cardiology 61th Scientific Session.
    • 27 Mar 2012 Results presented at the 61st Annual Scientific Session of the American College of Cardiology.
    • 16 Nov 2011 Primary endpoint 'Pharmacokinetic-parameters' has been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top